Table 1 Clinical assessments for CAD patients in CCADS
Domain | Assessment |
|---|---|
Demographics | age, gender, educational level, contact information |
Medical history | |
vascular risk factors | American Heart Association guideline [21] |
migraine | classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain [22] |
I CTD* | Ehlers-Danlos syndrome, Marfan Syndrome, Loeys-Dietz syndrome, etc. [23] |
autoimmune diseases | SLE, Becet’s disease, Sjogren’s syndrome, etc. |
mild trauma | neck manipulation or overextension (within 2 weeks prior to symptom onset) [24] |
infection | within 2 weeks prior to symptom onset |
Personal history | |
smoking | a structured questionnaire embedded in CRF |
alcohol use | a structured questionnaire embedded in CRF |
risk factor control | hypertension, migraine, etc. |
Clinical presentations | |
stroke | clinical stroke syndrome (sudden neurological dysfunction lasting >24 h, with no apparent cause other than that of vascular origin) |
TIA | rapidly evolving focal neurological deficit, without positive phenomena such as twitches, jerks or myoclonus, with no other than vascular cause lasting less than 24 h |
cranial nerve palsy | peripheral hypoglossal nerve or facial nerve palsy |
headache | new onset headache; severity, nature, location or frequency change |
Horner syndrome | Miosis, partial ptosis, loss of hemifacial sweating |
stroke severity | NIHSS [25] |
stoke risk after TIA | ABCD2 scores [26] |
Functional independence | mRS [27] |
Treatment | |
antithrombotic drugs | aspirin, clopidogrel, NOAC |
reperfusion therapy | intravenous thrombolysis, intra-arterial thrombolysis, endovascular intervention |
other medicines | statin, antihypertensive therapy, antidiabetics |
medication compliance | a structured questionnaire |
time | time from symptom onset to treatment, and treatment duration |